Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Newbury Pharmaceuticals AB's Enterprise Value is kr65.32 Mil.
Newbury Pharmaceuticals AB's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2026 was kr-15.08 Mil. Therefore, Newbury Pharmaceuticals AB's EV-to-FCF for today is -4.33.
The historical rank and industry rank for Newbury Pharmaceuticals AB's EV-to-FCF or its related term are showing as below:
OSTO:NEWBRY'
s EV-to-FCF Range Over the Past 10 Years
Min: -21.67 Med: -3.46 Max: -1.03
Current: -4.86
During the past 5 years, the highest EV-to-FCF of Newbury Pharmaceuticals AB was -1.03. The lowest was -21.67. And the median was -3.46.
OSTO:NEWBRY's EV-to-FCF is ranked worse than 100% of 559
companies
in the Drug Manufacturers industry
Industry Median: 20.58
vs OSTO:NEWBRY: -4.86
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Newbury Pharmaceuticals AB (OSTO:NEWBRY) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Newbury Pharmaceuticals AB's PE Ratio (TTM) for today is calculated as:
Newbury Pharmaceuticals AB's share price for today is kr2.48.
Newbury Pharmaceuticals AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.987.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Newbury Pharmaceuticals AB EV-to-FCF Related Terms
Newbury Pharmaceuticals AB EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:NEWBRY vs ZTS, UTHR, VTRS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newbury Pharmaceuticals AB EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Newbury Pharmaceuticals AB's EV-to-FCF falls into.
Newbury Pharmaceuticals AB's current Enterprise Value is kr65.32 Mil.
Newbury Pharmaceuticals AB's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-15.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newbury Pharmaceuticals AB (OSTO:NEWBRY) has a EV-to-FCF of -4.33 as of Aug. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Newbury Pharmaceuticals AB and its competitors. According to the industry distribution chart, Newbury Pharmaceuticals AB ranks #999999 out of 559 companies in the Drug Manufacturers industry.
Is Newbury Pharmaceuticals AB's EV-to-FCF too high?
Newbury Pharmaceuticals AB's current EV-to-FCF is -4.33. Based on the distribution chart, Newbury Pharmaceuticals AB ranks #999999 out of 559 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 42/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Newbury Pharmaceuticals AB ranks #999999 out of 559 companies for EV-to-FCF. This places Newbury Pharmaceuticals AB in the lower half of its industry. The industry median EV-to-FCF is 20.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.58, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Newbury Pharmaceuticals AB and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newbury Pharmaceuticals AB's current EV-to-FCF is -4.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB (OSTO:NEWBRY) is currently considered Modestly Undervalued. The stock's GF Value™ is kr3.20, compared to a current price of kr2.48 — trading 22.5% below its estimated fair value. The current EV-to-FCF is -4.33. Newbury Pharmaceuticals AB's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (OSTO:NEWBRY), the current EV-to-FCF is -4.33 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newbury Pharmaceuticals AB (OSTO:NEWBRY) Overvalued in 2026?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued.
The current stock price of kr2.48 is trading 22.5% below its estimated GF Value™ of kr3.20.
GuruFocus considers Newbury Pharmaceuticals AB to be Modestly Undervalued.
Key valuation signals for OSTO:NEWBRY:
EV-to-FCF: -4.33
GF Value™: kr3.20 vs. price of kr2.48 (22.5% below fair value)
No single metric tells the full story. See the OSTO:NEWBRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
42GF Score
Get the complete analysis for OSTO:NEWBRY
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NEWBRY has been successfully added to your 
